

Performance Against Time to Target

REC Ref	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Min Number Of Patients	Max Number Of Patients	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Participants Recruited	Reason For Closure Of Trial
13/LO/0150	119662	NCRN561 : The regorafenib in patients with hepatocellular carcinoma (RESORCE)	Number Agreed	2	2	Date Agreed	01/08/2015	1	07/10/2015	1	Recruitment Finished
13/LO/0418	112763	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	Number Agreed	2	2	Date Agreed	31/10/2017	1	18/02/2016	1	Withdrawn By Host
14/SC/1014	156913	CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in pancreatic adenocarcinoma	Number Agreed	2	2	Date Agreed	30/09/2015	4	08/01/2016	5	Recruitment Finished
14/YH/1124	160884	EXTEND (2819MA1002)	Number Agreed	3	3	Date Agreed	28/02/2016	0	04/02/2016	0	Recruitment Finished
14/SC/0181	148882	Elagolix in Endometriosis Associated Pain - Extension	Number Agreed	1	1	Date Agreed	31/12/2015	1	31/12/2015	1	Recruitment Finished
14/LO/1490	158617	CANC-3574 - Nivolumab (BMS-936558) in Stage III (unresectable) or stage IV Melanoma (CA209-172)	Number Agreed	3	3	Date Agreed	30/10/2015	3	18/01/2016	3	Recruitment Finished
14/YH/1090	158372	QUIET-1	Number Agreed	4	4	Date Agreed	31/12/2015	0	08/10/2015	0	Withdrawn By Sponsor
15/LO/0920	181642	SMT11004: Paediatric Subjects with Duchenne Muscular Dystrophy (DMD)	Number Agreed	1	1	Date Agreed	19/02/2016	1	18/02/2016	1	Recruitment Finished
15/LO/0273	149700	M14-011: Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)	Number Agreed	8	8	Date Agreed	29/02/2016	1	18/03/2016	1	Recruitment Finished
15/SS/0186	190856	Protocol 083: MK5172A + Sofosbuvir +/-RBV in Cirrhotic GT3 Subjects (MK-5172-083)	Number Agreed	6	6	Date Agreed	24/03/2016	4	24/03/2016	4	Recruitment Finished
15/EE/0100	163708	MK5172/ MK3682 with MK8742 or MK8408 in HCV GT1, GT2, and GT4 Infected Subjects	Number Agreed	5	5	Date Agreed	01/02/2016	4	25/03/2016	4	Recruitment Finished
14/YH/1269	160993	CHIL3644 I.V. Tapentadol in post op pain	Number Agreed	1	1	Date Agreed	30/06/2016	0	04/04/2016	0	Withdrawn By Host
15/NW/0573	174966	CHIL4421 (NP25737)	Number Agreed	1	1	Date Agreed	30/01/2017	0	10/05/2016	0	Withdrawn By Sponsor

Performance Against Time to Target

15/LO/0691	174324	Checkmate - 171	Number Agreed	4	4	Date Agreed	01/04/2016	4	01/06/2016	8	Recruitment Finished
14/SC/1311	155403	MCRN3165 (SD744) Cubist PSI Osteomyelitis	Number Agreed	3	3	Date Agreed	30/06/2016	0	09/06/2016	0	Recruitment Finished
15/SC/0397	183591	An evaluation of the tolerance and acceptability of Neocate Junior, an amino acid based feed for children.	Number Agreed	3	3	Date Agreed	31/07/2016	2	31/07/2016	2	Recruitment Finished
15/LO/0900	167412	630-0012 Pulmonx LIBERATE Study	Number Agreed	4	4	Date Agreed	31/10/2016	2	30/09/2016	2	Recruitment Finished
14/LO/1798	161154	NCRN - 3312 - MPDL3280A vs Chemotherapy in Urothelial Bladder Cancer	Number Agreed	4	4	Date Agreed	01/04/2016	2	05/01/2016	2	Withdrawn By Sponsor
13/YH/0201	129722	Sativex Severe Spasticity	Number Agreed	6	6	Date Agreed	31/12/2015	5	01/07/2016	5	Recruitment Finished
13/LO/0161	114841	MAESTRO: Macitentan in Eisenmenger Syndrome AC-055-305 (CCRN 2104)	Number Agreed	3	3	Date Agreed	01/10/2016	1	20/07/2016	1	Recruitment Finished
15/NW/0631	185354	OKAH-193 Varicella vaccine study in the second year of life	Number Agreed	100	100	Date Agreed	31/07/2016	100	27/07/2016	100	Recruitment Finished
14/SC/1425	159287	GX29185	Number Agreed	7	7	Date Agreed	31/10/2016	7	28/07/2016	7	Recruitment Finished
15/YH/0407	183603	Single Dose of MK0517 for Prevention of CINV in Paediatric Subjects	Number Agreed	4	4	Date Agreed	08/08/2016	0	03/08/2016	0	Withdrawn By Sponsor
15/LO/0517	170613	CANC - 4281 - YOSEMITE	Number Agreed	5	5	Date Agreed	30/08/2016	1	08/08/2016	1	Recruitment Finished
13/NW/0321	130144	MCRN234 (WA28118)	Number Agreed	2	2	Date Agreed	30/10/2016	2	10/08/2016	2	Recruitment Finished
15/EE/0405	189187	DIAB 4501	Number Agreed	4	4	Date Agreed	15/08/2016	4	15/08/2016	4	Recruitment Finished
15/LO/0413	171579	Safety and Efficacy of Brimonidine-DDS in patients with GA-AMD	Number Agreed	3	3	Date Agreed	31/08/2016	3	09/09/2016	3	Recruitment Finished
13/SC/0007	118729	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients with Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Unresectable Melanoma.	Number Agreed	5	5	Date Agreed	01/08/2016	4	28/09/2016	4	Recruitment Finished
16/HRA/0128	198232	NEUTROPENIC SEPSIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER	Number Agreed	18	18	Date Agreed	31/07/2016	22	31/07/2016	22	Recruitment Finished
15/LO/1166	178877	Efficacy and Safety of RTH258 versus Afibercept	Number Agreed	4	4	Date Agreed	26/04/2016	6	30/04/2016	6	Recruitment Finished